Ionis Pharmaceuticals Files 8-K Report
Ticker: IONS · Form: 8-K · Filed: Sep 9, 2024 · CIK: 874015
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
IONIS filed an 8-K, no major news yet.
AI Summary
On September 9, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific new transactions or material events requiring immediate disclosure beyond the filing itself. The company is incorporated in Delaware and headquartered in Carlsbad, California.
Why It Matters
This filing indicates Ionis Pharmaceuticals is adhering to its reporting obligations with the SEC, though it does not disclose new material information at this time.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report for 'Other Events' and does not contain information that inherently increases risk.
Key Numbers
- 000-19125 — Commission File Number (SEC identifier for Ionis Pharmaceuticals)
- 33-0336973 — IRS Employer Identification No. (Tax identification for Ionis Pharmaceuticals)
Key Players & Entities
- IONIS PHARMACEUTICALS, INC. (company) — Registrant
- September 9, 2024 (date) — Date of report
- Carlsbad, CA (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' as required by the SEC, indicating adherence to reporting obligations without disclosing specific new material events.
When was this 8-K report filed?
This 8-K report was filed on September 9, 2024.
Where is Ionis Pharmaceuticals, Inc. headquartered?
Ionis Pharmaceuticals, Inc. is headquartered at 2855 Gazelle Court, Carlsbad, CA 92010.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
Does this filing disclose any new financial results or significant business developments?
No, this filing is categorized under 'Other Events' and does not appear to disclose new financial results or significant business developments.
Filing Stats: 2,825 words · 11 min read · ~9 pages · Grade level 13.9 · Accepted 2024-09-09 16:33:00
Key Financial Figures
- $2.2 billion — June 30, 2024, we have earned more than $2.2 billion in revenues from our SPINRAZA collabora
- $1.7 billion — RAZA collaboration, including more than $1.7 billion in royalties on sales of SPINRAZA. QAL
Filing Documents
- d881331d8k.htm (8-K) — 60KB
- 0001193125-24-215939.txt ( ) — 183KB
- ions-20240909.xsd (EX-101.SCH) — 2KB
- ions-20240909_lab.xml (EX-101.LAB) — 17KB
- ions-20240909_pre.xml (EX-101.PRE) — 11KB
- d881331d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements regarding Ionis' expectations with respect to Ionis' business and the therapeutic and commercial potential of Ionis' marketed medicines, including SPINRAZA (nusinersen), QALSODY (tofersen), WAINUA (eplontersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen), as well as Ionis' additional medicines in development and technologies, the achievement of potential regulatory approvals for our medicines in development and the anticipated timing of any such approvals. Words such as "anticipate," "believe," "could," "continue," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. For such statements, Ionis claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Ionis' expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering, macroeconomic and geopolitical events, Ionis' commercial products and the medicines in Ionis' pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Additional factors that could cause actual results to differ materially from those stated or implied by Ionis' forward-looking state